I agree with you, it is likely the herd will only commence buying once the FDA confirm they will accept stem cell therapy as a viable treatment.
But more importantly, the herd flowing into an under-researched area of the market will force analysts to take a closer look, much the same way they did with BNPL from 2018 onwards. It is at this point the companies that can demonstrate they have a competitive advantage will really shine, and hence why myself and most others on this forum are invested in Cynata.
CYP Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)